13360-66-2 Usage
Uses
Used in Pharmaceutical Industry:
3,9-Dihydroxy-8-methoxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one is used as a pharmaceutical compound for its potential anti-inflammatory and anti-cancer properties. Its antioxidant nature makes it a promising candidate for the development of new drugs targeting various inflammatory and cancer-related conditions.
Used in Natural Products Industry:
In the natural products industry, 3,9-Dihydroxy-8-methoxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one is used as an ingredient in health supplements and cosmetics due to its antioxidant properties. It is being investigated for its potential to provide health benefits such as reducing inflammation and supporting overall well-being.
Used in Research and Development:
3,9-Dihydroxy-8-methoxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one is used in research and development for its potential applications in various fields. Scientists are studying its pharmacological properties to better understand its mechanisms of action and explore its potential uses in treating various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 13360-66-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,3,6 and 0 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 13360-66:
(7*1)+(6*3)+(5*3)+(4*6)+(3*0)+(2*6)+(1*6)=82
82 % 10 = 2
So 13360-66-2 is a valid CAS Registry Number.
13360-66-2Relevant academic research and scientific papers
Structure-activity relationship of wedelolactone analogues: Structural requirements for inhibition of Na+,K+-ATPase and binding to the central benzodiazepine receptor
Pocas, Elisa S.C.,Lopes, Daniele V.S.,da Silva, Alcides J.M.,Pimenta, Paulo H.C.,Leitao, Fernanda B.,Netto, Chaquip D.,Buarque, Camilla D.,Brito, Flavia V.,Costa, Paulo R.R.,Noel, Francois
, p. 7962 - 7966 (2007/10/03)
Coumestans 2a-i, bearing different patterns of substitution in A- and D-rings, were synthesized and evaluated as inhibitors of kidney Na+,K+-ATPase and ligands for the central benzodiazepine (BZP) receptor. The presence of a hydroxyl group in position 2 favours the effect on Na+,K+-ATPase but decreases the affinity for the BZP receptor, allowing the design of more selective molecules than the natural wedelolactone. On the other hand, the presence of a catechol in ring D is important for the effect on both molecular targets.
